NASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis $25.31 -0.27 (-1.06%) Closing price 04:00 PM EasternExtended Trading$25.08 -0.22 (-0.89%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Zai Lab Stock (NASDAQ:ZLAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zai Lab alerts:Sign Up Key Stats Today's Range$24.73▼$25.4550-Day Range$18.18▼$27.0052-Week Range$15.96▼$33.97Volume290,197 shsAverage Volume860,004 shsMarket Capitalization$2.88 billionP/E RatioN/ADividend YieldN/APrice Target$37.25Consensus RatingModerate Buy Company Overview Zai Lab Ltd. (NASDAQ: ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases with significant unmet medical needs. The company’s research and development activities span oncology, autoimmune and inflammatory disorders, infectious diseases, and neuroscience. Founded in 2014 by Samantha Du, Zai Lab has built a portfolio through internal research as well as licensing and collaboration agreements with international pharmaceutical and biotechnology companies. Its products and partnered therapies have included treatments such as ZEJULA (niraparib) for certain ovarian cancers, QINLOCK (ripretinib) for gastrointestinal stromal tumors, and NUZYRA (omadacycline), an antibiotic used to treat certain bacterial infections. Zai Lab has historically concentrated on developing and commercializing innovative therapies in China while expanding its research, development and commercial capabilities internationally. The company’s operations have included activities in China, the United States and other global markets, supported by partnerships intended to broaden access to its medicines. Zai Lab was founded and led by Samantha Du, a biotechnology executive with experience in drug development and company building.AI Generated. May Contain Errors. Read More Zai Lab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreZLAB MarketRank™: Zai Lab scored higher than 44% of companies evaluated by MarketBeat, and ranked 617th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingZai Lab has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialZai Lab has a consensus price target of $37.25, representing about 47.2% upside from its current price of $25.31.Amount of Analyst CoverageZai Lab has only been the subject of 3 research reports in the past 90 days.Read more about Zai Lab's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($2.37) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -14.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -14.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zai Lab's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.54% of the float of Zai Lab has been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 9.19.Change versus previous monthShort interest in Zai Lab has recently increased by 1.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.05 News SentimentZai Lab has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Zai Lab this week, compared to 3 articles on an average week. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $235,145.00 in company stock.Percentage Held by Insiders4.88% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zai Lab's insider trading history. Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZLAB Stock News HeadlinesCritical Comparison: Zai Lab (NASDAQ:ZLAB) vs. Anixa Biosciences (NASDAQ:ANIX)October 7 at 5:15 AM | americanbankingnews.comIs Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?October 4 at 10:02 AM | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 7 at 1:00 AM | InvestorPlace (Ad)Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)September 29, 2026 | marketscreener.comMZai Lab Ltd (ZLAB)September 24, 2026 | in.investing.comZai Lab Limited (ZLAB)September 11, 2026 | finance.yahoo.comZ.ai shares surge 8% after releasing new AI model running only on Chinese chipsAugust 26, 2026 | cnbc.comZai Lab: Revenue Growth And Zoci's Upside OptionalityAugust 19, 2026 | seekingalpha.comSee More Headlines ZLAB Stock Analysis - Frequently Asked Questions How have ZLAB shares performed this year? Zai Lab's stock was trading at $17.64 at the beginning of 2026. Since then, ZLAB shares have increased by 43.5% and is now trading at $25.31. How were Zai Lab's earnings last quarter? Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) issued its quarterly earnings results on Tuesday, June, 30th. The company reported ($0.50) EPS for the quarter. The firm earned $106.31 million during the quarter. Zai Lab had a negative trailing twelve-month return on equity of 27.43% and a negative net margin of 41.86%. When did Zai Lab IPO? Zai Lab (ZLAB) raised $142 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 8,333,333 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include NVIDIA (NVDA), Tesla (TSLA), Intel (INTC), Meta Platforms (META), Advanced Micro Devices (AMD), Baidu (BIDU) and Home Depot (HD). Company Calendar Last Earnings6/30/2026Today10/07/2026Investor update10/23/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ZLAB's financial health is in the Green zone, according to TradeSmith. ZLAB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZLAB CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees1,784Year Founded2014Price Target and Rating Average Price Target for Zai Lab$37.25 High Price Target$45.00 Low Price Target$32.00 Potential Upside/Downside+47.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$175.54 million Net Margins-41.86% Pretax Margin-42.42% Return on Equity-27.43% Return on Assets-16.72% Debt Debt-to-Equity RatioN/A Current Ratio2.13 Quick Ratio1.92 Sales & Book Value Annual Sales$460.16 million Price / Sales6.26 Cash FlowN/A Price / Cash FlowN/A Book Value$6.39 per share Price / Book3.96Miscellaneous Outstanding Shares113,780,000Free Float108,230,000Market Cap$2.88 billion OptionableOptionable Beta0.73 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ZLAB) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
